Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AFMD Affimed	$0.71 -1.8%	$0.98	$0.70 ▼ $8.95	$11.43M	2.22	303,108 shs	113,465 shs
IXHL Incannex Healthcare	$0.68 +0.5%	$1.36	$0.62 ▼ $3.60	$12.15M	7.49	38,527 shs	17,424 shs
MRKR Marker Therapeutics	$1.14 -7.3%	$1.60	$1.10 ▼ $5.99	$12.21M	1.51	58,826 shs	119,212 shs
NBY NovaBay Pharmaceuticals	$0.59 +0.0%	$0.64	$0.36 ▼ $9.08	$3.40M	0.73	208,406 shs	112,459 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AFMD Affimed	-7.41%	-17.06%	-29.79%	-39.23%	-86.35%
IXHL Incannex Healthcare	-4.72%	-15.44%	-46.73%	-68.09%	-81.16%
MRKR Marker Therapeutics	-3.15%	-3.91%	-19.61%	-60.45%	-71.40%
NBY NovaBay Pharmaceuticals	-3.78%	-5.65%	-3.31%	-2.66%	-84.04%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AFMD Affimed	4.4117 of 5 stars	3.4	5.0	4.3	3.3	0.0	1.3
IXHL Incannex Healthcare	0.92 of 5 stars	0.0	3.0	0.0	3.8	1.7	0.0
MRKR Marker Therapeutics	4.0032 of 5 stars	3.8	3.0	3.9	2.0	0.8	0.6
NBY NovaBay Pharmaceuticals	1.5468 of 5 stars	3.5	0.0	0.0	0.6	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AFMD Affimed	2.80	Moderate Buy	$13.50	1,801.68% Upside
IXHL Incannex Healthcare	0.00	N/A	N/A	N/A
MRKR Marker Therapeutics	3.50	Strong Buy	$13.17	1,054.97% Upside
NBY NovaBay Pharmaceuticals	3.00	Buy	$0.85	45.27% Upside

Current Analyst Ratings Breakdown

Latest NBY, IXHL, AFMD, and MRKR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/1/2025	MRKR Marker Therapeutics	WBB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$12.50 ➝ $12.50
3/5/2025	MRKR Marker Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
2/10/2025	MRKR Marker Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 4/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AFMD Affimed	$877K	13.03	N/A	N/A	$4.19 per share	0.17
IXHL Incannex Healthcare	$98K	123.93	N/A	N/A	$0.05 per share	13.60
MRKR Marker Therapeutics	$3.31M	3.69	N/A	N/A	$1.58 per share	0.72
NBY NovaBay Pharmaceuticals	$13.84M	0.25	N/A	N/A	$4.25 per share	0.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AFMD Affimed	-$114.66M	N/A	0.00	N/A	N/A	-7,836.26%	-193.84%	-107.24%	4/1/2025 (Estimated)
IXHL Incannex Healthcare	-$18.46M	-$1.39	N/A	∞	N/A	N/A	-289.30%	-154.96%	5/21/2025 (Estimated)
MRKR Marker Therapeutics	-$8.24M	N/A	0.00	N/A	N/A	-179.74%	-89.63%	-71.62%	5/21/2025 (Estimated)
NBY NovaBay Pharmaceuticals	-$9.64M	-$53.72	N/A	N/A	N/A	-102.72%	-7,293.78%	-158.41%	N/A

Latest NBY, IXHL, AFMD, and MRKR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/1/2025	N/A	AFMD Affimed	-$0.91	-$0.6246	+$0.2854	N/A	$0.14 million	N/A
3/31/2025	Q4 2024	MRKR Marker Therapeutics	-$0.28	-$0.42	-$0.14	-$0.42	$5.25 million	$1.22 million
2/14/2025	Q2 2025	IXHL Incannex Healthcare	N/A	-$0.33	N/A	-$0.33	N/A	$10.00 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AFMD Affimed	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A
NBY NovaBay Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AFMD Affimed	0.13	1.93	1.93
IXHL Incannex Healthcare	2.47	1.80	1.65
MRKR Marker Therapeutics	N/A	3.15	3.15
NBY NovaBay Pharmaceuticals	N/A	1.15	0.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AFMD Affimed	30.82%
IXHL Incannex Healthcare	0.43%
MRKR Marker Therapeutics	22.39%
NBY NovaBay Pharmaceuticals	23.25%

Insider Ownership

Company	Insider Ownership
AFMD Affimed	3.80%
IXHL Incannex Healthcare	26.53%
MRKR Marker Therapeutics	14.50%
NBY NovaBay Pharmaceuticals	0.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AFMD Affimed	200	16.10 million	15.49 million	Optionable
IXHL Incannex Healthcare	3	17.86 million	13.12 million	Not Optionable
MRKR Marker Therapeutics	60	10.71 million	9.16 million	Not Optionable
NBY NovaBay Pharmaceuticals	30	5.82 million	4.88 million	Not Optionable

NBY, IXHL, AFMD, and MRKR Headlines

Recent News About These Companies

NovaBay Pharmaceuticals Delays Yearly Report Filing

April 1 at 8:39 AM | tipranks.com

NovaBay Pharmaceuticals (NYSE:NBY) Earns Hold Rating from Analysts at StockNews.com

March 26, 2025 | americanbankingnews.com

NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders

March 7, 2025 | businesswire.com

NovaBay fails to gain shareholder approval for dissolution

February 5, 2025 | msn.com

NovaBay Pharmaceuticals Inc NBY

February 2, 2025 | morningstar.com

NovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's Why

December 25, 2024 | zacks.com

NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders

December 19, 2024 | businesswire.com

NovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special Meeting

December 9, 2024 | businesswire.com

NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024

November 22, 2024 | businesswire.com

NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price

November 6, 2024 | businesswire.com

NovaBay Pharmaceuticals To Sell Assets Of Its Avenova Brand - Quick Facts

September 21, 2024 | markets.businessinsider.com

NBY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NovaBay Pharmaceuticals, Inc.'s Avenova Brand and Business Is Fair to Shareholders

September 20, 2024 | businesswire.com

Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals

September 20, 2024 | finance.yahoo.com

Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals

September 20, 2024 | prnewswire.com

NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets

September 20, 2024 | businesswire.com

NOVABAY PHARMAC. DL-,01 (B9P0.MU)

September 14, 2024 | sg.finance.yahoo.com

NovaBay Pharmaceuticals Supports National Dry Eye Awareness Month with Multiple Avenova Product Promotions

June 28, 2024 | businesswire.com

NovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE American

June 7, 2024 | businesswire.com

Why Is NovaBay Pharmaceuticals (NBY) Stock Down 39% Today?

May 30, 2024 | investorplace.com

NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates

May 29, 2024 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBY, IXHL, AFMD, and MRKR Company Descriptions

Affimed NASDAQ:AFMD

$0.71 -0.01 (-1.84%)

Closing price 03:59 PM Eastern

Extended Trading

$0.71 0.00 (-0.41%)

As of 04:05 PM Eastern

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Incannex Healthcare NASDAQ:IXHL

$0.68 +0.00 (+0.52%)

Closing price 03:49 PM Eastern

Extended Trading

$0.62 -0.06 (-8.82%)

As of 04:50 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

Marker Therapeutics NASDAQ:MRKR

$1.14 -0.09 (-7.32%)

Closing price 04:00 PM Eastern

Extended Trading

$1.14 0.00 (0.00%)

As of 04:22 PM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

NovaBay Pharmaceuticals NYSE:NBY

$0.59 +0.00 (+0.02%)

As of 03:59 PM Eastern

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time